Table 1
| SWOG/ Support |
STUDY | R E G |
O P E N |
ARM | ACCR. GOAL |
TOTAL REGS. |
REGS. LAST 12 Month |
REGS. LAST 6 Month |
REGS. LAST 3 Month |
REGS. LAST 30 DAYS |
REGS. LAST 7 DAYS |
DATE OF FIRST REG. |
# of ACT. INSTs |
# of CURR IRBs |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SWOG | S1007-Breast,Adj,N1,Endocrine+/-Chemo | 1 | Y | 1 Recurrence Score testing | 9400 | 9383 | 0 | 0 | 0 | 0 | 0 | 02/28/2011 | 404 | 194 |
| 9383 | 0 | 0 | 0 | 0 | 0 | |||||||||
| 2 | Y | 2 Chemo and Endocrine Therapy | 5000 | 2547 | 2 | 0 | 0 | 0 | 0 | 02/28/2011 | ||||
| 3 Endocrine Therapy Alone | 2536 | 1 | 0 | 0 | 0 | 0 | ||||||||
| 5083 | 3 | 0 | 0 | 0 | 0 | |||||||||
| S1207-Brst,Adj,Endocrine+/-Everolimus | 1 | Y | 1 Blinded drug + Endocrine | 1900 | 867 | 177 | 83 | 46 | 19 | 4 | 09/12/2013 | 441 | 212 | |
| 2 Blinded drug + Endocrine | 866 | 166 | 75 | 33 | 7 | 2 | ||||||||
| 1733 | 343 | 158 | 79 | 26 | 6 | |||||||||
| S1222-Brst,Fulv. +/- Ever. +/- Anastr. | 1 | T | 1 Blinded treatment | 840 | 12 | 0 | 0 | 0 | 0 | 0 | 05/15/2014 | 16 | 5 | |
| 2 Blinded treatment | 12 | 0 | 0 | 0 | 0 | 0 | ||||||||
| 3 Blinded treatment | 13 | 0 | 0 | 0 | 0 | 0 | ||||||||
| 37 | 0 | 0 | 0 | 0 | 0 | |||||||||
| S1416-Brst, TNBC/BRCA, Cis+/- ABT-888 | 1 | Y | 1 Blinded Drug + Cisplatin | 333 | 130 | 50 | 7 | 7 | 3 | 0 | 09/15/2016 | 266 | 132 | |
| 2 Blinded Drug + Cisplatin | 138 | 59 | 17 | 17 | 8 | 3 | ||||||||
| 268 | 109 | 24 | 24 | 11 | 3 | |||||||||
| S1418-Breast, Adj, TNBC, MK-3475 (Pembrolizumab) | 1 | Y | 1 Tissue for PD-L1 testing | 1000 | 331 | 241 | 129 | 66 | 24 | 4 | 01/18/2017 | 465 | 209 | |
| 331 | 241 | 129 | 66 | 24 | 4 | |||||||||
| 2 | Y | 2 Observation | 1000 | 142 | 104 | 50 | 26 | 9 | 2 | 01/18/2017 | ||||
| 3 MK-3475 (Pembrolizumab) | 140 | 101 | 54 | 28 | 8 | 0 | ||||||||
| 282 | 205 | 104 | 54 | 17 | 2 | |||||||||
| Yes | A011106-Breast, Neoadj, ALTERNATE study | 1 | E | Total Registrations | 77 | 27 | 21 | 13 | 3 | 2 | 04/29/2014 | 121 | ||
| 77 | 27 | 21 | 13 | 3 | 2 | |||||||||
| E1Z11-Brst,Genetic Predictors of AIMSS | 1 | E | Total Registrations | 156 | 12 | 6 | 5 | 1 | 1 | 08/13/2013 | 34 | |||
| 156 | 12 | 6 | 5 | 1 | 1 | |||||||||
| NRGBR003-Brst,Adj,TNBC,AC -> WP +/- Carbo | 1 | E | Total Registrations | 64 | 21 | 13 | 5 | 2 | 0 | 10/16/2015 | 223 | |||
| 64 | 21 | 13 | 5 | 2 | 0 | |||||||||
| NRGBR005-Br, Stg II&IIIA, Post NAdj Chemo Br Conserv | 1 | E | Total Registrations | 4 | 4 | 4 | 3 | 1 | 0 | 06/22/2018 | 11 | 11 | ||
| 4 | 4 | 4 | 3 | 1 | 0 | |||||||||
| No | A011401-Breast, adj, Stage II/III HER2-, weight loss | 1 | E | Total Registrations | 187 | 110 | 57 | 27 | 9 | 2 | 10/05/2016 | 244 | ||
| 187 | 110 | 57 | 27 | 9 | 2 | |||||||||
| 2 | E | Total Registrations | 169 | 103 | 52 | 26 | 9 | 1 | 10/05/2016 | |||||
| 169 | 103 | 52 | 26 | 9 | 1 | |||||||||
| A011502-Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo | 1 | E | Total Registrations | 56 | 38 | 24 | 6 | 4 | 1 | 03/20/2017 | 445 | 230 | ||
| 56 | 38 | 24 | 6 | 4 | 1 | |||||||||
| A221405-Breast, ET interruption, Pregnancy Outcomes | 1 | E | Total Registrations | 13 | 9 | 4 | 2 | 0 | 0 | 05/08/2017 | 130 | 68 | ||
| 13 | 9 | 4 | 2 | 0 | 0 | |||||||||
| B51-Breast, Regional Nodal XRT | 1 | E | Total Registrations | 32 | 12 | 7 | 3 | 0 | 0 | 06/13/2014 | 212 | |||
| 32 | 12 | 7 | 3 | 0 | 0 | |||||||||
| B55-Brst, Adj Olaparib for BRCA,TNBC | 1 | E | Total Registrations | 67 | 22 | 10 | 3 | 0 | 0 | 12/15/2014 | 440 | 186 | ||
| 67 | 22 | 10 | 3 | 0 | 0 | |||||||||
| 2 | E | Total Registrations | 32 | 12 | 8 | 4 | 0 | 0 | 12/15/2014 | |||||
| 32 | 12 | 8 | 4 | 0 | 0 | |||||||||
| E2112-Brst,Adv,Exemestane+/-Entinostat | 1 | E | Total Registrations | 59 | 18 | 12 | 7 | 1 | 0 | 04/01/2015 | 162 | |||
| 59 | 18 | 12 | 7 | 1 | 0 | |||||||||
| EA1131-Brst, TNBC, Post-op Chemo vs Obs | 0 | E | Total Registrations | 20 | 6 | 2 | 2 | 2 | 1 | 11/12/2015 | 131 | |||
| 20 | 6 | 2 | 2 | 2 | 1 | |||||||||
| 1 | P | Total Registrations | 11 | 4 | 2 | 0 | 0 | 0 | 11/12/2015 | |||||
| 11 | 4 | 2 | 0 | 0 | 0 | |||||||||
| EA1151-Brst, Tomosynthesis Mammographic Screening | 1 | E | Total Registrations | 209 | 209 | 154 | 65 | 25 | 6 | 01/30/2018 | 148 | 74 | ||
| 209 | 209 | 154 | 65 | 25 | 6 | |||||||||
| NRGBR002-Brst, OMBC, II-III, SoC +/- SBRT and/or SA | 1 | E | Total Registrations | 1 | 0 | 0 | 0 | 0 | 0 | 09/22/2017 | 306 | 136 | ||
| 1 | 0 | 0 | 0 | 0 | 0 | |||||||||